Back to Newsroom

MabVax Therapeutics Closes $2.1 Million Private Placement Financing

SAN DIEGO, Feb. 6, 2018 /PRNewswire/ — MabVax Therapeutics Holdings, Inc. (the “Company”) (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced today the closing of a private financing for a total of $2.1 million.